Answers are grounded in this paper and cite their sources.
SIMULATED, NOT MEASURED. Blueprint package derived from 'Programmable White Blood Cells: A Two-Marker Specificity-Logic Design for Engineered T Cells' (DOI: 10.5281/zenodo.24108795). Specifies, at principle, parameter and process-design level only, an engineered T cell in which a priming receptor for marker A induces a killing receptor for marker B, so firing requires both markers on the same target cell. Includes the construct architecture as functional components, an ordered manufacturing process design with acceptance criteria from the source numbers (discrimination ratio 25.0 versus 2.5 single-receptor, 51.0-fold suppression on marker-B-only healthy tissue, healthy-tissue cytokine risk index reduced 36.7-fold, persistence half-life 28 days, burden coverage 1.5x stated as thin), a safety case printing on-target/off-tumour risk as the dominant remaining risk, the source's five quantitative stopping conditions, and a costed process estimate of US $114,000-$278,000 per single-patient course (midpoint $196,000) under stated assumptions. No wet-lab protocol, no sequences, nothing described as built, manufactured or tested in any organism.
No takes yet. Share an insight, caveat, or question.
William Alexander Aldred (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: